3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
13
Stomach Neoplasms
3
Neoplasm Metastasis
3
Carcinoma, Hepatocellular
3
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Mesothelioma, Malignant
1
Melanoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Brain Neoplasms
1
Interventions
Pemetrexed
7
Cisplatin
7
Cyclophosphamide
5
pembrolizumab
4
fludarabine
4
Platinum
3
Drug Therapy
3
aldesleukin
2
Nivolumab
2
Ipilimumab
2
Interleukin-2
2
1,2-diaminocyclohexaneplatinum II citrate
2
vatalanib
1
spartalizumab
1
regorafenib
1
napabucasin
1
methoxyamine
1
fludarabine phosphate
1
enzalutamide
1
cediranib
1
avelumab
1
atezolizumab
1
anetumab ravtansine
1
Vorinostat
1
Thiostrepton
1
Tetrahydrouridine
1
Radiosurgery
1
Megestrol Acetate
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Mesothelioma, Malignant
×
regorafenib
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled